Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents

Buder, Kathrin; Zirngibl, Matthias; Bapistella, Sascha; Meerpohl, Joerg J; Strahm, Brigitte; Bassler, Dirk; Weitz, Marcus

doi:10.1002/14651858.cd009759.pub4

Cited by 1 publication

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…77,85,86 One of the direct effects of ECP is the induction of lymphocyte and monocyte apoptosis mediated via photosensitizing agents generating free oxygen radicals upon exposure to UV light, leading to oxidative stress and cell death. 87 Additionally, ECP has been known to play a role in the transition from Th1 to Th2 immune response, as well as increasing the number of Treg. 88 Multiple studies have demonstrated the efficacy of ECP in refractory GvHD after HSCT; however, limited studies have shown the effectiveness of ECP in GvHD after ITx.…”

Section: Extracorporeal Photopheresismentioning

confidence: 99%

“…However, based on our center's experience, given the promising data surrounding ruxolitinib in HSCT and case reports in ITx, earlier intervention in SR-GvHD with JAK inhibitors in patients could be considered. [86][87][88] We would also consider the use of rituximab in patients who develop Epstein-Barr viral viremia during their course of treatment. 9 Data available demonstrate variable outcomes to current therapies that target TNF-α, CD20, or T-cell markers impacted by ATG.…”

Section: Lessons Learned From Hsct and Potential For Future Pharmacol...mentioning

confidence: 99%

See 1 more Smart Citation

Current Advances in Graft-Versus-Host Disease After Intestinal Transplantation

et al. 2023

View full text Add to dashboard Cite

Graft-versus-host disease (GvHD) remains a potentially fatal complication following intestinal transplant (ITx). Over the past decade, advances in the understanding of the pathophysiology of this complex immunological phenomenon have led to the reassessment of the host systemic immune response and have created a gateway for novel preventive and therapeutic strategies. Although sufficient evidence dictates the use of corticosteroids as a first-line option, the treatment for refractory disease remains contentious and lacks a standardized therapeutic approach. Timely diagnosis remains crucial, and the advent of chimerism detection and immunological biomarkers have transformed the identification, prognostication, and potential for survival after GvHD in ITx. The objectives of the following review aim to discuss the clinical and diagnostic features, pathophysiology, advances in immune biomarkers, as well as therapeutic opportunities in the prevention and treatment of GvHD in ITx.

show abstract